All In MedTech

FDA Clearance Tracker · P060038-S033

Mitroflow Aortic Pericardial Heart Valve

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 21, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 21, 2019

Approved

Time to decision

227 days

Received Apr 8, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P060038-S033
Device name
Mitroflow Aortic Pericardial Heart Valve
Applicant location
Burnaby
Received
Apr 8, 2019
Decided
Nov 21, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P060038

Device type

Device class
Class III

Every decision under product code LWR

FDA's approval statement

As written in FDA's record.

Approval to terminate NEMO post-approval study.

Source documents

Other decisions for Corcym Canada Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.